Roche’s Genentech has sued Amgen for not giving up the info Genentech experts need to mount a patent infringement attack on Amgen’s biosimilar for Avastin, its…

Friday, AZ showed that it's PARP inhibitor Lynparza, currently approved in ovarian cancer, is more than a one-trick pony.

PRA and Takeda are building a Japan JV, Sun's quarterly profits dropped, ASLAN posted positive top-line phase 2 data for varlitinib.

​​​​​​​Ex-Turing Pharma CEO Martin Shkreli can’t get away from his bad rep.

Stada already had two interested buyers in the mix as of earlier this week. And now, it’s got three.

President Trump told Robert Kennedy Jr. he won't "back down" from plans to create vax safety commission, despite guaranteed "uproar"…

PhRMA's joining Marathon Pharma's critics, not only by criticizing the company's $89K price tag on a new-but-old drug, but also hinting that it…

It’s no secret that Sanofi has struggled of late at the dealmaking table. But why? The deal prospectus from former target Actelion buyer J&J offers some…

As activist investor William Ackman, a thorn in Zoetis' side for two years, reported that he'd sold off his stake, the animal health giant reported…

Pharma